An injectable subcutaneous colon-specific immune niche for the treatment of ulcerative colitis

Nat Biomed Eng. 2024 Oct;8(10):1243-1265. doi: 10.1038/s41551-023-01136-9. Epub 2023 Dec 4.

Abstract

As a chronic autoinflammatory condition, ulcerative colitis is often managed via systemic immunosuppressants. Here we show, in three mouse models of established ulcerative colitis, that a subcutaneously injected colon-specific immunosuppressive niche consisting of colon epithelial cells, decellularized colon extracellular matrix and nanofibres functionalized with programmed death-ligand 1, CD86, a peptide mimic of transforming growth factor-beta 1, and the immunosuppressive small-molecule leflunomide, induced intestinal immunotolerance and reduced inflammation in the animals' lower gastrointestinal tract. The bioengineered colon-specific niche triggered autoreactive T cell anergy and polarized pro-inflammatory macrophages via multiple immunosuppressive pathways, and prevented the infiltration of immune cells into the colon's lamina propria, promoting the recovery of epithelial damage. The bioengineered niche also prevented colitis-associated colorectal cancer and eliminated immune-related colitis triggered by kinase inhibitors and immune checkpoint blockade.

MeSH terms

  • Animals
  • B7-H1 Antigen / immunology
  • B7-H1 Antigen / metabolism
  • Colitis, Ulcerative* / drug therapy
  • Colitis, Ulcerative* / immunology
  • Colon* / immunology
  • Colon* / pathology
  • Disease Models, Animal
  • Extracellular Matrix / metabolism
  • Female
  • Injections, Subcutaneous
  • Macrophages / drug effects
  • Macrophages / immunology
  • Mice
  • Mice, Inbred C57BL
  • Nanofibers / chemistry

Substances

  • B7-H1 Antigen